Last $3.10 USD
Change Today 0.00 / 0.00%
Volume 656.0
CYCC On Other Exchanges
As of 9:43 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

cyclacel pharmaceuticals inc (CYCC) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/20/13 - $5.50
52 Week Low
08/14/13 - $2.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cyclacel pharmaceuticals inc (CYCC) Related Businessweek News

No Related Businessweek News Found

cyclacel pharmaceuticals inc (CYCC) Details

Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops and commercializes mechanism-targeted drugs to treat human cancers and other serious diseases. The company’s oncology development programs include sapacitabine, an orally-available nucleoside analogue that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and seliciclib, an orally-available 2nd generation CDK inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its other oncology development programs comprise CYC065, an orally-available 2nd generation CDK-2, -5, -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; and Sapacitabine + Seliciclib, which is in Phase I trials for the treatment of cancer. The company’s non-oncology programs comprise cell cycle inhibitors for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

18 Employees
Last Reported Date: 03/26/14
Founded in 1992

cyclacel pharmaceuticals inc (CYCC) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $713.4K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $463.1K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $442.4K
Compensation as of Fiscal Year 2013.

cyclacel pharmaceuticals inc (CYCC) Key Developments

Cyclacel Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 11:00 AM

Cyclacel Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 11:00 AM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States. Speakers: Paul McBarron, Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer, Executive Vice President of Finance & Administration, Secretary and Executive Director.

Cyclacel Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Cyclacel Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company's net loss applicable to common shareholders of $4.9 million, or $0.25 per basic and diluted share, compared to a net loss applicable to common shareholders of $11.6 million, or $1.18 per basic and diluted share, for the first quarter of 2013. Revenue was $0.4 million compared to $0.2 million for the same period of the previous year. Operating loss was $4.051 million against $5.410 million a year ago. Loss from continuing operations before taxes was $3.356 million against $5.446 million a year ago. Net loss from continuing operations was $3.098 million or $1.18 per basic and diluted share against $4.877 million or $0.25 per basic and diluted share a year ago.

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2014 Results on May 13, 2014

Cyclacel Pharmaceuticals, Inc. announced that they will report Q1, 2014 results at 4:30 PM, Eastern Daylight on May 13, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYCC:US $3.10 USD 0.00

CYCC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYCC.
View Industry Companies

Industry Analysis


Industry Average

Valuation CYCC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 47.7x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 33.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYCLACEL PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at